In accordance with its characterisation as a valid model of hypermutated/MSI-H human CRC – and consistent with human consensus molecular subtype 1 (CMS1) tumours (28, 29) – the MC38 model is responsive to immune checkpoint inhibition of the PD-1/PD-L1 axis (15, 30). The gene discussed is CD274; the disease is neoplasm.